<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 /home/lopez/grobid/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Efficacy and safety of prostate artery embolization on lower urinary tract symptoms related to benign prostatic hyperplasia: a systematic review and meta-analysis</title>
			</titleStmt>
			<publicationStmt>
				<publisher>Dove Medical Press Ltd.</publisher>
				<availability status="unknown"><p>Copyright Dove Medical Press Ltd.</p>
				</availability>
				<date type="published" when="2016-11-11">11 November 2016</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Xiao-Yan</forename><surname>Wang</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Urology</orgName>
								<orgName type="institution" key="instit1">Beijing Tian Tan Hospital</orgName>
								<orgName type="institution" key="instit2">Capital Medical University</orgName>
								<address>
									<settlement>Beijing</settlement>
									<country>People&apos;s Republic of China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Huan-Tao</forename><surname>Zong</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Urology</orgName>
								<orgName type="institution" key="instit1">Beijing Tian Tan Hospital</orgName>
								<orgName type="institution" key="instit2">Capital Medical University</orgName>
								<address>
									<settlement>Beijing</settlement>
									<country>People&apos;s Republic of China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yong</forename><surname>Zhang</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Urology</orgName>
								<orgName type="institution" key="instit1">Beijing Tian Tan Hospital</orgName>
								<orgName type="institution" key="instit2">Capital Medical University</orgName>
								<address>
									<settlement>Beijing</settlement>
									<country>People&apos;s Republic of China</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Department of Urology</orgName>
								<orgName type="department" key="dep2">Dong Cheng District</orgName>
								<orgName type="institution" key="instit1">Beijing Tian Tan Hospital</orgName>
								<orgName type="institution" key="instit2">Capital Medical University</orgName>
								<address>
									<addrLine>No 6 Tiantan Xi Li</addrLine>
									<postCode>100050</postCode>
									<settlement>Beijing</settlement>
									<country>People&apos;s Republic</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Efficacy and safety of prostate artery embolization on lower urinary tract symptoms related to benign prostatic hyperplasia: a systematic review and meta-analysis</title>
					</analytic>
					<monogr>
						<title level="j" type="main">Clinical Interventions in Aging</title>
						<title level="j" type="abbrev">CIA</title>
						<idno type="eISSN">1178-1998</idno>
						<imprint>
							<publisher>Dove Medical Press Ltd.</publisher>
							<biblScope unit="volume">Volume11</biblScope>
							<biblScope unit="page" from="1609" to="1622"/>
							<date type="published" when="2016-11-11">11 November 2016</date>
						</imprint>
					</monogr>
					<idno type="DOI">10.2147/cia.s119241</idno>
					<idno type="PMID">27956827</idno>
					<idno type="PMCID">PMC5113931</idno>
					<ptr type="open-access" target="https://www.dovepress.com/getfile.php?fileID=33534" />
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.6.2-SNAPSHOT" ident="GROBID" when="2020-08-13T23:26+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>lower urinary tract symptoms</term>
					<term>benign prostatic hyperplasia</term>
					<term>meta-analysis</term>
					<term>prostate artery embolization</term>
				</keywords>
			</textClass>
			<abstract>
				<p>Background: Prostate artery embolization (PAE) is emerging and is a promising minimally invasive therapy that improves lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH). The purpose of this article was to evaluate the efficacy and safety of PAE on LUTS related to BPH. Materials and methods: A literature review was performed to identify all published articles of PAE for BPH. The sources included MEDLINE, EMBASE and Cochrane Library from 1980 to 2016. A systematic review and meta-analysis was conducted. The outcome measurements were combined by calculating the mean difference with 95% confidence interval. Statistical analysis was carried out using Review Manager 5.3.0. Results: Twelve studies involving 840 participants were included. Compared with baseline, the International Index of Erectile Function (IIEF-5; International Prostate Symptom Score) scores, the quality of life scores, peak urinary flow rate (Q max) and postvoid residual volume all had significant improvements during the 24-month follow-up (all P,0.00001). Both prostate volume (PV) and prostate-specific antigen had significant decrease during the 12-month follow-up (P,0.00001 and P=0.005, respectively), except postoperative 24 months (P=0.47 and P=0.32, respectively). The IIEF-5 short form scores had significant increase at postoperative 6 months (P=0.002) and 12 months (P,0.0001), except postoperative 1 month (P=0.23) and 24 months (P=0.21). For large volume (PV $80 mL) BPH, the results were similar. There were no life-threatening complications. Conclusion: PAE is an effective, safe and well-tolerable treatment for LUTS related to BPH, including large volume (PV $80 mL) BPH, with a good short-term follow-up. Studies with large number of cases and longer follow-up time are needed to validate our results.</p>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p>Lower urinary tract symptoms (LUTS) are main complaints resulting from benign prostatic hyperplasia (BPH), which is one of the most common diseases of aging men. <ref type="bibr" target="#b0">1</ref> LUTS can range in severity and have a significant impact on the quality of life (QoL).</p><p>The current treatment options include watchful waiting, medical therapy and surgical intervention. The patients refractory to preliminary treatments can be treated with surgical intervention. Transurethral resection of the prostate (TURP) is the gold standard therapy for LUTS/BPH and, for many years, has been considered the surgical treatment of choice and the standard of care when other treatment methods fail. <ref type="bibr" target="#b1">2</ref> However, TURP has significant complications, including short-term bleeding, dilutional hyponatremia, sexual dysfunction and incontinence. The complication rate is higher for patients with large volume BPH. <ref type="bibr" target="#b2">3</ref> Recently, prostate artery embolization (PAE) has started emerging and is a promising minimally invasive therapy that improves LUTS related to BPH and is associated with a decrease in prostate volume (PV). <ref type="bibr" target="#b3">4</ref> However, it is reported that as many as 25% of patients show no significant improvement in symptoms and peak flow rate. In addition, the average reduction rate in the PV after PAE was only 20%. <ref type="bibr" target="#b4">5</ref> The aim of this meta-analysis was to evaluate the efficacy and safety of PAE on LUTS related to BPH, which may help urologists make better choices in the case of elderly patients with large volume BPH.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Materials and methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Search strategy</head><p>A comprehensive literature search was carried out by two independent reviewers using MEDLINE (from 1980 to 2016), EMBASE (from 1980 to 2016) and the Cochrane Central Register of Controlled Trials. The reference lists of the retrieved studies were also checked. The following search terms were used: "prostate artery embolization", "lower urinary tract symptoms" and "benign prostatic hyperplasia".</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Inclusion criteria</head><p>Studies that met the following criteria were included: 1) a study design that included PAE for BPH; 2) a study that provided data on International Prostate Symptom Score (IPSS), QoL, PV, prostate-specific antigen (PSA), peak urine flow rate (Q max ), postvoid residual (PVR) volume and International Index of Erectile Function (IIEF-5) short form at different follow-up times, and 3) a study where its full text could be accessed. If these inclusion criteria were not met, then the study was excluded.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Trial selection</head><p>When the same study was published in various journals or in different years, the most frequently cited one was used. If the same group of researchers studied a group of subjects with multiple experiments, then each study was included. Together, we discussed each of the studies that were included and excluded.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Quality assessment</head><p>The quality of included studies was assessed using the Newcastle-Ottawa scale generating a maximum of nine stars to each study, including four stars for the selection of participants, two stars for the comparability of participants and three stars for the assessment of outcomes. Quality was assigned according to the scores so that seven to nine stars indicated high quality, four to six stars indicated middle quality and zero to three stars indicated low quality.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Data extraction</head><p>Two independent reviewers extracted the data using a predesigned form. The following information was collected from each study: 1) the name of the first author and the publication year; 2) the sample size; 3) the country in which the study was conducted; 4) data on IPSS, QoL, PV, PSA, Q max , PVR volume and IIEF-5 at different follow-up times and 5) the number of participants with complications. Any disputes were resolved by group consensus.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p>Statistical analysis was carried out using Review Manager 5.3.0. The changes in seven functional indexes were determined as differences between baseline and study completion. Outcome measurements were combined by calculating the mean difference with 95% confidence interval (CI). To quantify the effect of heterogeneity test result, I 2 heterogeneity test was used. A random-effects model was used if I 2 value was .50%; if not, a fixed-effects model was used. Publication bias was evaluated using the funnel plot. <ref type="figure" target="#fig_0">Figure 1</ref> shows the flow diagram of the study selection process. Finally, there were nine articles involving 12 studies eligible for this meta-analysis. <ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref><ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref> All of the 12 studies reported the baseline IPSSs, QoL scores, PV, PSA levels, Q max , PVR volume and IIEF-5 scores. All 12 studies excluded patients with malignancy, advanced atherosclerosis and tortuosity of the iliac arteries and/or prostate arteries, secondary renal insufficiency, large bladder diverticula or stones, neurogenic bladder, detrusor muscle failure, active urinary tract infection and unregulated coagulation parameters. The main characteristic and quality assessment of eligible studies are presented in <ref type="table" target="#tab_3">Table 1</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Characteristic and quality assessment of eligible studies</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Changes after PAE IPSSs</head><p>Six studies involving 582 participants, five studies involving 451 participants, six studies involving 479 participants and three studies involving 117 participants included data representing IPSS changes at postoperative 1 month <ref type="figure">(Figure 2A</ref>), 6 months ( <ref type="figure">Figure 2B</ref>), 12 months ( <ref type="figure">Figure 2C</ref>) and 24 months ( <ref type="figure">Figure 2D)</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Qol scores</head><p>Nine studies involving 660 participants, eight studies involving 528 participants, six studies involving 414 participants and three studies involving 117 participants included data representing QoL score changes at postoperative 1 month ( <ref type="figure">Figure 3A</ref>), 6 months ( <ref type="figure">Figure 3B</ref>), 12 months ( <ref type="figure">Figure 3C</ref>) and 24 months ( <ref type="figure">Figure 3D)</ref> </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Prostate volume</head><p>Five studies involving 507 participants, five studies involving 386 participants, six studies involving 366 participants and three studies involving 106 participants included data representing PV changes at postoperative 1 month ( <ref type="figure">Figure 4A</ref>), 6 months ( <ref type="figure">Figure 4B</ref>), 12 months ( <ref type="figure">Figure 4C</ref>) and 24 months ( <ref type="figure">Figure 4D</ref>), respectively.</p><p>Compared </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Prostate-specific antigen</head><p>Five studies involving 520 participants, five studies involving 383 participants, six studies involving 379 participants and three studies involving 104 participants included data representing PSA changes at postoperative 1 month ( <ref type="figure">Figure 5A</ref>), 6 months ( <ref type="figure">Figure 5B</ref>), 12 months ( <ref type="figure">Figure 5C</ref>) and 24 months ( <ref type="figure">Figure 5D</ref>), respectively.</p><p>Compared with baseline, PSA had significant decreases at postoperative 1 month (WMD −0.80, 95% CI −1.44 to −0.16, P=0.01), 6 months (WMD −1.15, 95% CI −1.69 to −0.60, P,0.0001) and 12 months (WMD −0.97, 95% CI −1.65 to −0.29, P=0.005). Although PSA was also less at postoperative 24 months (WMD −0.80, 95% CI −2.37 to −0.77), the difference was not statistically significant (P=0.32).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Q max</head><p>Six studies involving 502 participants, five studies involving 368 participants, six studies involving 368 participants and three studies involving 104 participants included data representing Q max changes at postoperative 1 month ( <ref type="figure">Figure 6A</ref>), 6 months ( <ref type="figure">Figure 6B</ref>), 12 months ( <ref type="figure">Figure 6C</ref>) and 24 months ( <ref type="figure">Figure 6D</ref>), respectively.</p><p>Compared with baseline, Q max had significant increases at postoperative 1 month (WMD 4.40, 95% CI 3.00-5.80, P,0.00001), 6 months (WMD 4.71, 95% CI 2.62-6.81, P,0.0001), 12 months (WMD 5.60, 95% CI 4.19-7.02, P,0.00001) and 24 months (WMD 5.89, 95% CI 5.08-6.7, P,0.00001).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>PVR volume</head><p>Six studies involving 476 participants, five studies involving 348 participants, six studies involving 369 participants and three studies involving 104 participants included data representing PVR volume changes at postoperative 1 month ( <ref type="figure">Figure 7A</ref>), 6 months ( <ref type="figure">Figure 7B</ref>), 12 months ( <ref type="figure">Figure 7C</ref>) and 24 months ( <ref type="figure">Figure 7D</ref>), respectively.    </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>IIEF-5 scores</head><p>Nine studies involving 609 participants, eight studies involving 463 participants, six studies involving 372 participants and three studies involving 102 participants included data representing IIEF-5 score changes at postoperative 1 month ( <ref type="figure">Figure 8A</ref>), 6 months ( <ref type="figure">Figure 8B</ref>), 12 months ( <ref type="figure">Figure 8C</ref>) and 24 months ( <ref type="figure">Figure 8D</ref>), respectively.</p><p>Compared with baseline, the IIEF-5 scores were slightly increased at postoperative 1 month (WMD 0.49, 95%</p><p>CI −0.30-1.28), but the difference was not statistically significant (P=0.23). There were significant increases at postoperative 6 months (WMD 1.29, 95% CI 0.48-2.10, P=0.002) and 12 months (WMD 1.36, 95% CI 0.69-2.02, P,0.0001). However, a slight decrease turned up at postoperative 24 months (WMD −0.81, 95% CI −2.08-0.46), which was not statistically significant (P=0.21).</p><p>Changes after PAE on large volume (PV $80 mL) BPH Four studies, involving 179 participants, included data representing changes in the large volume BPH (PV.80 mL). <ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref><ref type="bibr" target="#b11">[12]</ref> All the results matched the earlier findings, except that PSA had no obvious decrease during the 3-month follow-up and that the IIEF-5 scores had no significant changes during the 12-month follow-up. The comparison of changes after  Bagla et al, <ref type="bibr" target="#b9">10</ref> Li et al, <ref type="bibr" target="#b10">11</ref> and Wang et al. <ref type="bibr" target="#b11">12</ref> Abbreviations: BPH, benign prostatic hyperplasia; CI, confidence interval; IIEF-5, International Index of Erectile Function; IPSS, International Prostate Symptom Score; MD, mean difference; PAE, prostate artery embolization; PSA, prostate-specific antigen; PV, prostate volume; PVR, postvoid residual; Q max , peak urinary flow rate; QoL, quality of life.</p><p>PAE on large volume (PV $80 mL) BPH with baseline is presented in <ref type="table" target="#tab_5">Table 2</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Complications</head><p>There were no life-threatening complications. Only one serious adverse event was seen in the study by Pisco et al: <ref type="bibr" target="#b13">14</ref> a case of a small area (1.5 cm 2 ) of bladder wall ischemia in the right side of the base without involvement of the urethra or urethral orifices. The area of ischemia at the bladder base was removed by surgery without further complications.</p><p>Burning sensation in urethra (87/840, 10.4%) during the procedure seemed to be the main complication. Hematuria occurred in 57/840 (6.8%) participants, hematospermia in 49/840 (5.8%), a small rectal bleeding in 38/840 (4.5%) and inguinal hematoma in 16/840 (1.9%). All these complications disappeared spontaneously without any treatment. In all, 21/840 (2.9%) participants developed urinary tract infection and all responded to suitable antibiotics. A total of 80/840 (9.5%) participants had acute urinary retention (AUR) at 1-3 days after PAE. For relief, a temporary bladder catheter was placed, and they were able to void spontaneously before discharge. There were no cases of sexual impotence or retrograde ejaculation. Complications reported in the eligible studies are presented in <ref type="table" target="#tab_6">Table 3</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p>PAE was first utilized in the 1970s to treat refractory bleeding following prostatic interventions as well as for intractable hematuria. <ref type="bibr" target="#b14">15</ref> It demonstrated a successful reduction in PV without serious complications in human beings in 2010. <ref type="bibr" target="#b1">2</ref> The rationale for PAE is that prostate ischemia leads to PV reduction and hence clinical improvement. <ref type="bibr" target="#b15">16</ref> In this meta-analysis, compared with baseline, there were significant improvements in the IPSSs (−12.74 points), QoL scores (−2.07 points), PV (−17.33 mL), PSA (−0.80 ng/mL), Q max (+4.4 mL/s) and PVR volume (−56.23 mL) after PAE at postoperative 1 month. It implied that PAE could take effect quickly. Furthermore, the IPSSs (−15.62 points), QoL scores (−2.15 points), Q max (+5.89 mL/s) and PVR volume (−49.07 mL) still had significant improvements during the 24-month follow-up, suggesting that PAE had good control of symptoms within 2 years.</p><p>For PV and PSA, significant decreases were found during the 12-month follow-up, but not at postoperative 24 months. We thought that the effect of PAE cannot be maintained in the long-term period. Besides prostate size increasing with age, revascularization of the prostatic arteries after PAE may play a role in prostate regrowth. Pisco et al <ref type="bibr" target="#b12">13</ref> observed this kind of revascularization in their patients with second PAE. Interestingly, the IPSSs still had a significant decrease despite prostatic enlargement at postoperative 24 months. This may suggest that physical reduction of the obstructing tissue was not the only reason for the improvement in LUTS after PAE. In terms of the IIEF-5 scores, there was no significant increase until 6 months after PAE. The epidemiological evidence had suggested a clear and clinically meaningful association between LUTS and sexual dysfunction that was independent of age and comorbidity. <ref type="bibr" target="#b16">17</ref> Along with the continuous improvement in LUTS, the IIEF-5 scores started to increase.</p><p>In addition, patients with large volume (PV $80 mL) BPH are often elderly and may have severe comorbidities. They have increased operative risk of undergoing TURP/open surgery or refuse any surgical treatment. <ref type="bibr" target="#b17">18</ref> In this meta-analysis, for large volume (PV $80 mL) BPH, there were significant improvements in the IPSSs (−18.32 points), QoL scores (−2.50 points), PV (−47.58 mL), Q max (+6.00 mL/s) and PVR volume (−76.80 mL) after PAE during the 12-month follow-up, and there were no lifethreatening complications. PAE does offer the ability to treat BPH in these patients, due to its minimally invasive nature with low morbidity and the possibility to use local anesthetic without sedation. <ref type="bibr" target="#b7">8</ref> Subsequent studies have further compared the clinical outcome of PAE versus TURP. Carnevale et al <ref type="bibr" target="#b18">19</ref> reported that both groups experienced significant improvement in IPSS, QoL, PV, and Q max during the 12-month follow-up. TURP resulted in significantly higher Q max and smaller PV than PAE but required spinal anesthesia and hospitalization, while IIEF scores were significantly higher in the PAE group. Gao et al <ref type="bibr" target="#b19">20</ref> reported a similar result during the 24-month follow-up, except that the PAE group showed more complications, mostly related to AUR (25.9%), postembolization syndrome (11.1%) and treatment failures (5.3% technical; 9.4% clinical).</p><p>Nevertheless, there are some limitations to our analysis. The major limitations include heterogeneity in the participants chosen, different materials and sizes of embolic agents and bilateral or unilateral embolization. The subgroup and sensitivity analysis or a random-effects model might reduce these limitations, but cannot eliminate. Additionally, the sample sizes of some included studies were small, and there was no long-term follow-up study. Data in the studies covered by this meta-analysis are insufficient to determine whether or not PAE is as good as TURP. Stratified trials with high volume and long follow-up time are awaited to strengthen the evidence and to update our findings.</p><p>PAE is an effective, safe and well-tolerable treatment for LUTS related to BPH, including large volume (PV $80 mL) BPH, with good short-term follow-up. Studies with large number of cases and longer follow-up time are needed to validate our results.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Clinical Interventions in Aging</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Publish your work in this journal</head><p>Submit your manuscript here: http://www.dovepress.com/clinical-interventions-in-aging-journal Clinical Interventions in Aging is an international, peer-reviewed journal focusing on evidence-based reports on the value or lack thereof of treatments intended to prevent or delay the onset of maladaptive correlates of aging in human beings. This journal is indexed on PubMed Central, MedLine, CAS, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress. com/testimonials.php to read real quotes from published authors.</p><p>Clinical Interventions in Aging 2016:11</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1</head><label>1</label><figDesc>The flow diagram of the study selection process.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2 AFigure 3 AFigure 4 AFigure 5 AFigure 6 AFigure 7 AFigure 8 A</head><label>2345678</label><figDesc>forest plot about IPSS changes after PAE at postoperative 1 month (A), 6 months (B), 12 months (C), and 24 months (D). Abbreviations: CI, confidence interval; IPSS, International Prostate Symptom Score; IV, intravenous; PAE, prostate artery embolization; SD, standard deviation. forest plot about QoL score changes after PAE at postoperative 1 month (A), 6 months (B), 12 months (C), and 24 months (D). Abbreviations: CI, confidence interval; IV, intravenous; PAE, prostate artery embolization; SD, standard deviation; QoL, quality of life. forest plot about PV changes after PAE at postoperative 1 month (A), 6 months (B), 12 months (C), and 24 months (D). Note: a Using the fixed-effects model.Abbreviations: CI, confidence interval; IV, intravenous; PAE, prostate artery embolization; PV, prostate volume; SD, standard deviation. forest plot about PSA changes after PAE at postoperative 1 month (A), 6 months (B), 12 months (C), and 24 months (D). Abbreviations: CI, confidence interval; IV, intravenous; PAE, prostate artery embolization; PSA, prostate-specific antigen; SD, standard deviation. forest plot about Q max changes after PAE at postoperative 1 month (A), 6 months (B), 12 months (C), and 24 months (D).Note: a Using the fixed-effects model. Abbreviations: CI, confidence interval; IV, intravenous; PAE, prostate artery embolization; SD, standard deviation; Q max , peak urinary flow rate. forest plot about PVR volume changes after PAE at postoperative 1 month (A), 6 months (B), 12 months (C), and 24 months (D). Abbreviations: CI, confidence interval; IV, intravenous; PAE, prostate artery embolization; PVR, postvoid residual; SD, standard deviation. forest plot about IIEF-5 score changes after PAE at postoperative 1 month (A), 6 months (B), 12 months (C), and 24 months (D). Abbreviations: CI, confidence interval; IIEF-5, International Index of Erectile Function; IV, intravenous; PAE, prostate artery embolization; SD, standard deviation.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head></head><label></label><figDesc>Data from Isaacson et al,<ref type="bibr" target="#b8">9</ref> </figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head></head><label></label><figDesc>, respectively. Compared with baseline, the QoL scores had significant decreases at postoperative 1 month (WMD −2.07, 95% CI −2.37 to −1.76, P,0.00001), 6 months (WMD −2.15, 95% CI −2.44 to −1.86, P,0.00001), 12 months (WMD −2.81, 95% CI −3.45 to −2.17, P,0.00001) and 24 months (WMD −2.15, 95% CI −2.60 to −1.69, P,0.00001).</figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head></head><label></label><figDesc>with baseline, PV had significant decreases at postoperative 1 month (WMD −17.33, 95% CI −21.19 to −13.47, P,0.00001), 6 months (WMD −31.62, 95% CI −46.75 to −16.48, P,0.0001) and 12 months (WMD −30.72, 95% CI −42.91 to −18.53, P,0.00001). Although PV was also less at postoperative 24 months (WMD −16.89, 95% CI −62.61 to −28.83), the difference was not statistically significant (P=0.47).</figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 1</head><label>1</label><figDesc>The main characteristic and quality assessment of eligible studies</figDesc><table><row><cell>Quality</cell><cell>assessment a</cell><cell>Four stars</cell><cell></cell><cell></cell><cell></cell><cell>seven stars</cell><cell></cell><cell></cell><cell></cell><cell>Five stars</cell><cell></cell><cell></cell><cell>seven stars</cell><cell>Three stars</cell><cell></cell><cell>Four stars</cell><cell>Four stars</cell><cell>Four stars</cell><cell>Four stars</cell><cell></cell><cell></cell><cell>six stars</cell><cell></cell><cell></cell><cell>Eight stars</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Three stars</cell><cell></cell></row><row><cell>Follow-up</cell><cell>(month)</cell><cell>1, 3, 9</cell><cell></cell><cell></cell><cell></cell><cell>1, 6, 12, 18,</cell><cell>24</cell><cell></cell><cell></cell><cell>12</cell><cell></cell><cell></cell><cell></cell><cell>1, 3</cell><cell></cell><cell>1, 3, 6</cell><cell></cell><cell></cell><cell>1, 3, 6, 12</cell><cell></cell><cell></cell><cell>1, 3, 6, 12, 24</cell><cell></cell><cell></cell><cell>1, 3, 6, 12,</cell><cell>18, 24</cell><cell></cell><cell></cell><cell></cell><cell>6</cell><cell></cell></row><row><cell>Outcome measures</cell><cell></cell><cell>IPSS, QoL, PV, PSA,</cell><cell>Q max , PVR volume, IIEF-5</cell><cell></cell><cell></cell><cell>IPSS, QoL, PV, PSA,</cell><cell>Q max , PVR volume, IIEF-5</cell><cell></cell><cell></cell><cell>IPSS, QoL, PV, PSA,</cell><cell>Q max , PVR volume, IIEF-5</cell><cell></cell><cell></cell><cell>IPSS, QoL, PV, PSA,</cell><cell>Q max , PVR volume, IIEF-5</cell><cell>QoL, IIEF-5</cell><cell></cell><cell></cell><cell>IPSS, QoL, PV, PSA,</cell><cell>Q max , PVR volume, IIEF-5</cell><cell></cell><cell>IPSS, QoL, PV, PSA,</cell><cell>Q max , PVR volume, IIEF-5</cell><cell></cell><cell>IPSS, QoL, PV, PSA,</cell><cell>Q max , PVR volume, IIEF-5</cell><cell></cell><cell></cell><cell></cell><cell>IPSS, QoL, PV, PSA,</cell><cell>Q max , PVR volume, IIEF-5</cell></row><row><cell>Other inclusion criteria</cell><cell></cell><cell>BPH patients with LUTS refractory to BPH-</cell><cell>related medical therapy or those who had an</cell><cell>indwelling urethral catheter due to refractory</cell><cell>urine retention</cell><cell>BPH patients, IPSS .18 and Qol scores $3,</cell><cell>refractory to medical treatment for at least</cell><cell>6 months; Q max #12 mL/s or those with acute</cell><cell>urinary retention</cell><cell>BPH patients, IPSS .18 and Qol scores $3,</cell><cell>refractory to medical treatment for at least</cell><cell>6 months; Q max #12 mL/s or those with acute</cell><cell>urinary retention</cell><cell>Previous trial of BPH medication, IPSS $18,</cell><cell>life expectancy .1 year</cell><cell>BPH patients with moderate-or severe-grade</cell><cell>symptoms</cell><cell></cell><cell>BPH patients, IPSS .12, Q max ,15 mL/s,</cell><cell>PSA ,4 ng/mL or PSA level between 4 and</cell><cell>10 ng/mL but negative prostate biopsy</cell><cell>BPH patients, IPSS .18 and Qol scores .3,</cell><cell>refractory to medical treatment for at least</cell><cell>6 months, Q max ,12 ml/s</cell><cell>BPH patients, IPSS .18, and QoL score $3,</cell><cell>refractory to medical treatment for at least</cell><cell>6 months; Q max ,12 mL/s, sexual dysfunction</cell><cell>or accepting the risk of developing sexual</cell><cell>dysfunction after treatment</cell><cell>BPH patients, IPSS .18 and Qol score $3,</cell><cell>refractory to medical treatment for at least</cell><cell>mL/s or those with acute 6 months; Q max ,12</cell><cell>urinary retention</cell></row><row><cell>PV (mL)</cell><cell></cell><cell>n</cell><cell></cell><cell></cell><cell></cell><cell>.30</cell><cell></cell><cell></cell><cell></cell><cell>.40</cell><cell></cell><cell></cell><cell></cell><cell>80-150</cell><cell></cell><cell>,50</cell><cell>50-80</cell><cell>.80</cell><cell>.80</cell><cell></cell><cell></cell><cell>.80</cell><cell></cell><cell></cell><cell>.40</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>n</cell><cell></cell></row><row><cell>Age</cell><cell>(years)</cell><cell>.50</cell><cell></cell><cell></cell><cell></cell><cell>.55</cell><cell></cell><cell></cell><cell></cell><cell>$75</cell><cell></cell><cell></cell><cell>,75</cell><cell>.40</cell><cell></cell><cell>.45</cell><cell></cell><cell></cell><cell>.65</cell><cell></cell><cell></cell><cell>.50</cell><cell></cell><cell></cell><cell>.45</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>.60</cell><cell></cell></row><row><cell>Country</cell><cell></cell><cell>Saudi Arabia</cell><cell></cell><cell></cell><cell></cell><cell>Portugal</cell><cell></cell><cell></cell><cell></cell><cell>China</cell><cell></cell><cell></cell><cell></cell><cell>UsA</cell><cell></cell><cell>UsA</cell><cell></cell><cell></cell><cell>China</cell><cell></cell><cell></cell><cell>China</cell><cell></cell><cell></cell><cell>Portugal</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Portugal</cell><cell></cell></row><row><cell>Study design</cell><cell></cell><cell>Retrospective study</cell><cell></cell><cell></cell><cell></cell><cell>Retrospective study</cell><cell></cell><cell></cell><cell></cell><cell>Prospective study</cell><cell></cell><cell></cell><cell></cell><cell>Prospective study</cell><cell></cell><cell>Prospective study</cell><cell></cell><cell></cell><cell>Prospective study</cell><cell></cell><cell></cell><cell>Prospective study</cell><cell></cell><cell></cell><cell>Prospective study</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Prospective study</cell><cell></cell></row><row><cell>Sample</cell><cell>size</cell><cell>22</cell><cell></cell><cell></cell><cell></cell><cell>186</cell><cell></cell><cell></cell><cell></cell><cell>47</cell><cell></cell><cell></cell><cell>100</cell><cell>12</cell><cell></cell><cell>16</cell><cell>26</cell><cell>36</cell><cell>22</cell><cell></cell><cell></cell><cell>109</cell><cell></cell><cell></cell><cell>250</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>14</cell><cell></cell></row><row><cell>Studies</cell><cell></cell><cell>Gabr et al 6</cell><cell></cell><cell></cell><cell></cell><cell>Bilhim et al 7</cell><cell></cell><cell></cell><cell></cell><cell>Wang et al 8</cell><cell></cell><cell></cell><cell>Wang et al 8</cell><cell>Isaacson et al 9</cell><cell></cell><cell>Bagla et al 10</cell><cell>Bagla et al 10</cell><cell>Bagla et al 10</cell><cell>li et al 11</cell><cell></cell><cell></cell><cell>Wang et al 12</cell><cell></cell><cell></cell><cell>Pisco et al 13</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Pisco et al 14</cell><cell></cell></row></table><note>Notes:a Seven to nine stars indicated high quality, four to six stars middle quality and zero to three stars low quality. "N" indicates not applicable. Abbreviations: AUA, American Urological Association Symptom Index; BPH, benign prostatic hyperplasia; IIEF-5, International Index of Erectile Function; IPSS, International Prostate Symptom Score; LUTS, lower urinary tract symptoms; PSA, prostate-specific antigen; PV, prostate volume; PVR, postvoid residual; Qmax , peak urinary flow rate; QoL, quality of life.</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head></head><label></label><figDesc>Compared with baseline, PVR volume had significant decreases at postoperative 1 month (WMD −56.23, 95% CI −76.02 to −36.34, P,0.00001), 6 months (WMD −66.82, 95% CI −89.34 to −44.29, P,0.00001), 12 months (WMD −82.69, 95% CI −113.64 to −51.74, P,0.00001) and 24 months (WMD −49.07, 95% CI −97.67 to −0.47, P=0.05).</figDesc><table /><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>Table 2 12 Variables 1 month 3 months 6 months 12 months MD (95% CI) P-value MD (95% CI) P-value MD (95% CI) P-value MD (95% CI) P-value</head><label>2</label><figDesc>Comparison of changes after PAE on large volume (PV $80 mL) BPH with baseline 9-</figDesc><table><row><cell>,0.00001</cell><cell></cell></row><row><cell>−17.09)</cell><cell></cell></row><row><cell>−18.32 (−19.54 to</cell><cell></cell></row><row><cell>,0.00001</cell><cell></cell></row><row><cell>−17.48)</cell><cell></cell></row><row><cell>−18.61 (−19.74 to</cell><cell></cell></row><row><cell>,0.00001</cell><cell></cell></row><row><cell>−16.94)</cell><cell></cell></row><row><cell>−17.97 (−19.00 to</cell><cell></cell></row><row><cell>,0.00001</cell><cell></cell></row><row><cell>−14.68)</cell><cell></cell></row><row><cell>−15.97 (−17.25 to</cell><cell></cell></row><row><cell>IPSSs</cell><cell>Qol scores</cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_6"><head>Table 3</head><label>3</label><figDesc>Complications reported in the eligible studies</figDesc><table><row><cell>Studies</cell><cell>Sample</cell><cell cols="2">Complications</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>size</cell><cell>Urethral</cell><cell>Urinary tract</cell><cell>Hematuria</cell><cell>Hematospermia</cell><cell>Rectal</cell><cell>AUR</cell><cell>Inguinal</cell></row><row><cell></cell><cell></cell><cell>burning</cell><cell>infection</cell><cell></cell><cell></cell><cell>bleeding</cell><cell></cell><cell>hematoma</cell></row><row><cell>Gabr et al 6</cell><cell>22</cell><cell>15</cell><cell>0</cell><cell>0</cell><cell>0</cell><cell>0</cell><cell>0</cell><cell>0</cell></row><row><cell>Bilhim et al 7</cell><cell>186</cell><cell>0</cell><cell>1</cell><cell>14</cell><cell>15</cell><cell>10</cell><cell>9</cell><cell>6</cell></row><row><cell>Wang et al 8</cell><cell>47</cell><cell>10</cell><cell>0</cell><cell>6</cell><cell>4</cell><cell>4</cell><cell>16</cell><cell>3</cell></row><row><cell>Wang et al 8</cell><cell>100</cell><cell>12</cell><cell>0</cell><cell>8</cell><cell>8</cell><cell>7</cell><cell>9</cell><cell>3</cell></row><row><cell>Isaacson et al 9</cell><cell>12</cell><cell>0</cell><cell>1</cell><cell>1</cell><cell>1</cell><cell>0</cell><cell>1</cell><cell>0</cell></row><row><cell>Bagla et al 10</cell><cell>78</cell><cell>0</cell><cell>1</cell><cell>0</cell><cell>0</cell><cell>0</cell><cell>0</cell><cell>1</cell></row><row><cell>li et al 11</cell><cell>22</cell><cell>8</cell><cell>0</cell><cell>3</cell><cell>2</cell><cell>3</cell><cell>7</cell><cell>0</cell></row><row><cell>Wang et al 12</cell><cell>109</cell><cell>19</cell><cell>0</cell><cell>11</cell><cell>9</cell><cell>8</cell><cell>31</cell><cell>3</cell></row><row><cell>Pisco et al 13</cell><cell>250</cell><cell>23</cell><cell>19</cell><cell>14</cell><cell>10</cell><cell>6</cell><cell>6</cell><cell>0</cell></row><row><cell>Pisco et al 14</cell><cell>14</cell><cell>0</cell><cell>2</cell><cell>0</cell><cell>0</cell><cell>0</cell><cell>1</cell><cell>0</cell></row><row><cell>Total</cell><cell>840</cell><cell>87</cell><cell>24</cell><cell>57</cell><cell>49</cell><cell>38</cell><cell>80</cell><cell>16</cell></row></table><note>Abbreviation: AUR, acute urinary retention.</note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">submit your manuscript | www.dovepress.com Dovepress Dovepress</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Clinical Interventions in Aging 2016:11 submit your manuscript | www.dovepress.com Dovepress Dovepress</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">submit your manuscript | www.dovepress.com Dovepress Dovepress Dovepress</note>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Disclosure</head><p>The authors report no conflicts of interest in this work.</p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Update on AUA Guideline on the Management of Benign Prostatic Hyperplasia</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kevin</forename><forename type="middle">T</forename><surname>Mcvary</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Claus</forename><forename type="middle">G</forename><surname>Roehrborn</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Andrew</forename><forename type="middle">L</forename><surname>Avins</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Michael</forename><forename type="middle">J</forename><surname>Barry</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Reginald</forename><forename type="middle">C</forename><surname>Bruskewitz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Robert</forename><forename type="middle">F</forename><surname>Donnell</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Harris</forename><forename type="middle">E</forename><surname>Foster</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chris</forename><forename type="middle">M</forename><surname>Gonzalez</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Steven</forename><forename type="middle">A</forename><surname>Kaplan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><forename type="middle">F</forename><surname>Penson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">James</forename><forename type="middle">C</forename><surname>Ulchaker</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">John</forename><forename type="middle">T</forename><surname>Wei</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.juro.2011.01.074</idno>
		<idno type="PMID">21420124</idno>
	</analytic>
	<monogr>
		<title level="j">The Journal of Urology</title>
		<title level="j" type="abbrev">The Journal of Urology</title>
		<idno type="ISSN">0022-5347</idno>
		<imprint>
			<biblScope unit="volume">185</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1793" to="1803" />
			<date type="published" when="2011-05" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Prostatic Artery Embolization as a Primary Treatment for Benign Prostatic Hyperplasia: Preliminary Results in Two Patients</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Francisco</forename><forename type="middle">Cesar</forename><surname>Carnevale</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Alberto</forename><forename type="middle">Azoubel</forename><surname>Antunes</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Joaquim</forename><forename type="middle">Mauricio</forename><surname>Da Motta Leal Filho</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Luciana</forename><forename type="middle">Mendes</forename><surname>De Oliveira Cerri</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ronaldo</forename><forename type="middle">Hueb</forename><surname>Baroni</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Antonio</forename><forename type="middle">Sergio Zafred</forename><surname>Marcelino</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Geraldo</forename><forename type="middle">Campos</forename><surname>Freire</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Airton</forename><forename type="middle">Mota</forename><surname>Moreira</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Miguel</forename><surname>Srougi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Giovanni</forename><forename type="middle">Guido</forename><surname>Cerri</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00270-009-9727-z</idno>
		<idno type="PMID">19908092</idno>
		<idno type="PMCID">PMC2841280</idno>
		<idno type="ark">ark:/67375/VQC-46STMK8Z-M</idno>
		<idno type="istexId">81CEC0DA821C7E06B4C0F76CCAE97263EB17816A</idno>
		<ptr type="open-access" target="https://link.springer.com/content/pdf/10.1007%2Fs00270-009-9727-z.pdf" />
	</analytic>
	<monogr>
		<title level="j">CardioVascular and Interventional Radiology</title>
		<title level="j" type="abbrev">Cardiovasc Intervent Radiol</title>
		<idno type="ISSN">0174-1551</idno>
		<idno type="ISSNe">1432-086X</idno>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="355" to="361" />
			<date type="published" when="2009-11-12" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Bipolar Versus Monopolar Transurethral Resection of the Prostate: A Prospective Randomized Trial Focusing on Bleeding Complications</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Stucki</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Marini</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Mattei</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Xafis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Boldini</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Danuser</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.juro.2014.08.137</idno>
		<idno type="PMID">25464004</idno>
	</analytic>
	<monogr>
		<title level="j">The Journal of Urology</title>
		<title level="j" type="abbrev">The Journal of Urology</title>
		<idno type="ISSN">0022-5347</idno>
		<imprint>
			<biblScope unit="volume">193</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="1371" to="1376" />
			<date type="published" when="2015-04" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Current Status of Prostate Artery Embolization for Lower Urinary Tract Symptoms: Review of World Literature</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Patrick</forename><surname>Jones</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Bhavan</forename><forename type="middle">Prasad</forename><surname>Rai</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Rajesh</forename><surname>Nair</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Bhaskar</forename><forename type="middle">K</forename><surname>Somani</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.urology.2015.05.011</idno>
		<idno type="PMID">26238328</idno>
	</analytic>
	<monogr>
		<title level="j">Urology</title>
		<title level="j" type="abbrev">Urology</title>
		<idno type="ISSN">0090-4295</idno>
		<imprint>
			<biblScope unit="volume">86</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="676" to="681" />
			<date type="published" when="2015-10" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Society of Interventional Radiology Position Statement: Prostate Artery Embolization for Treatment of Benign Disease of the Prostate</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Justin</forename><forename type="middle">P</forename><surname>Mcwilliams</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Michael</forename><forename type="middle">D</forename><surname>Kuo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Steven</forename><forename type="middle">C</forename><surname>Rose</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sandeep</forename><surname>Bagla</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Drew</forename><forename type="middle">M</forename><surname>Caplin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Emil</forename><forename type="middle">I</forename><surname>Cohen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Salomao</forename><surname>Faintuch</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">James</forename><forename type="middle">B</forename><surname>Spies</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Wael</forename><forename type="middle">E</forename><surname>Saad</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Boris</forename><surname>Nikolic</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jvir.2014.05.005</idno>
		<idno type="PMID">24993818</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Vascular and Interventional Radiology</title>
		<title level="j" type="abbrev">Journal of Vascular and Interventional Radiology</title>
		<idno type="ISSN">1051-0443</idno>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1349" to="1351" />
			<date type="published" when="2014-09" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Prostatic Artery Embolization: A Promising Technique in the Treatment of High-Risk Patients with Benign Prostatic Hyperplasia</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ahmed</forename><forename type="middle">H</forename><surname>Gabr</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mohamed</forename><forename type="middle">F</forename><surname>Gabr</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Basheer</forename><forename type="middle">N</forename><surname>Elmohamady</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Abul-Fotouh</forename><surname>Ahmed</surname></persName>
		</author>
		<idno type="DOI">10.1159/000447360</idno>
		<idno type="PMID">27322582</idno>
	</analytic>
	<monogr>
		<title level="j">Urologia Internationalis</title>
		<title level="j" type="abbrev">Urol Int</title>
		<idno type="ISSN">0042-1138</idno>
		<idno type="ISSNe">1423-0399</idno>
		<imprint>
			<biblScope unit="volume">97</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="320" to="324" />
			<date type="published" when="2016" />
			<publisher>S. Karger AG</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Predictors of Clinical Outcome after Prostate Artery Embolization with Spherical and Nonspherical Polyvinyl Alcohol Particles in Patients with Benign Prostatic Hyperplasia</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tiago</forename><surname>Bilhim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">João</forename><surname>Pisco</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">José</forename><forename type="middle">A</forename><surname>Pereira</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Nuno</forename><forename type="middle">Vasco</forename><surname>Costa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lúcia</forename><surname>Fernandes</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Luís</forename><surname>Campos Pinheiro</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Marisa</forename><surname>Duarte</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">António</forename><forename type="middle">G</forename><surname>Oliveira</surname></persName>
		</author>
		<idno type="DOI">10.1148/radiol.2016152292</idno>
		<idno type="PMID">27223621</idno>
		<ptr type="open-access" target="https://pubs.rsna.org/doi/pdf/10.1148/radiol.2016152292" />
	</analytic>
	<monogr>
		<title level="j">Radiology</title>
		<title level="j" type="abbrev">Radiology</title>
		<idno type="ISSN">0033-8419</idno>
		<idno type="ISSNe">1527-1315</idno>
		<imprint>
			<biblScope unit="volume">281</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="289" to="300" />
			<date type="published" when="2016-10" />
			<publisher>Radiological Society of North America (RSNA)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Prostatic artery embolization for the treatment of symptomatic benign prostatic hyperplasia in men ≥75 years: a prospective single-center study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mao</forename><forename type="middle">Qiang</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yan</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jie</forename><forename type="middle">Yu</forename><surname>Yan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kai</forename><surname>Yuan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Guo</forename><forename type="middle">Dong</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Feng</forename><surname>Duan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kai</forename><surname>Li</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00345-016-1771-0</idno>
		<idno type="PMID">26818021</idno>
	</analytic>
	<monogr>
		<title level="j">World Journal of Urology</title>
		<title level="j" type="abbrev">World J Urol</title>
		<idno type="ISSN">0724-4983</idno>
		<idno type="ISSNe">1433-8726</idno>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1275" to="1283" />
			<date type="published" when="2016-01-27" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Prostatic Artery Embolization Using Embosphere Microspheres for Prostates Measuring 80–150 cm3: Early Results from a US Trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ari</forename><forename type="middle">J</forename><surname>Isaacson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mathew</forename><forename type="middle">C</forename><surname>Raynor</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hyeon</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Charles</forename><forename type="middle">T</forename><surname>Burke</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jvir.2016.01.146</idno>
		<idno type="PMID">27106645</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Vascular and Interventional Radiology</title>
		<title level="j" type="abbrev">Journal of Vascular and Interventional Radiology</title>
		<idno type="ISSN">1051-0443</idno>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="709" to="714" />
			<date type="published" when="2016-05" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Comparative Analysis of Prostate Volume as a Predictor of Outcome in Prostate Artery Embolization</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sandeep</forename><surname>Bagla</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">John</forename><forename type="middle">B</forename><surname>Smirniotopoulos</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Julie</forename><forename type="middle">C</forename><surname>Orlando</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Arletta</forename><surname>Van Breda</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Venu</forename><surname>Vadlamudi</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jvir.2015.08.018</idno>
		<idno type="PMID">26428880</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Vascular and Interventional Radiology</title>
		<title level="j" type="abbrev">Journal of Vascular and Interventional Radiology</title>
		<idno type="ISSN">1051-0443</idno>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1832" to="1838" />
			<date type="published" when="2015-12" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Prostatic arterial embolization with small sized particles for the treatment of lower urinary tract symptoms due to large benign prostatic hyperplasia: preliminary results</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Q</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Duan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">Q</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">D</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Yuan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Chin Med J (Engl)</title>
		<imprint>
			<biblScope unit="volume">128</biblScope>
			<biblScope unit="issue">15</biblScope>
			<biblScope unit="page" from="2072" to="2077" />
			<date type="published" when="2015" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Prostatic arterial embolization for the treatment of lower urinary tract symptoms due to large (&gt;80 mL) benign prostatic hyperplasia: results of midterm follow-up from Chinese population</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mao</forename><forename type="middle">Qiang</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Li</forename><forename type="middle">Ping</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Guo</forename><forename type="middle">Dong</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kai</forename><surname>Yuan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kai</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Feng</forename><surname>Duan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jie</forename><forename type="middle">Yu</forename><surname>Yan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yan</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hai</forename><forename type="middle">Yan</forename><surname>Kang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Zhi</forename><forename type="middle">Jun</forename><surname>Wang</surname></persName>
		</author>
		<idno type="DOI">10.1186/s12894-015-0026-5</idno>
		<idno type="PMID">25887036</idno>
		<idno type="PMCID">PMC4403829</idno>
		<ptr type="open-access" target="https://bmcurol.biomedcentral.com/track/pdf/10.1186/s12894-015-0026-5" />
	</analytic>
	<monogr>
		<title level="j">BMC Urology</title>
		<title level="j" type="abbrev">BMC Urol</title>
		<idno type="ISSNe">1471-2490</idno>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">33</biblScope>
			<date type="published" when="2015-04-16" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Embolisation of prostatic arteries as treatment of moderate to severe lower urinary symptoms (LUTS) secondary to benign hyperplasia: results of short- and mid-term follow-up</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Joao</forename><forename type="middle">Martins</forename><surname>Pisco</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hugo</forename><surname>Rio Tinto</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Luís</forename><surname>Campos Pinheiro</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tiago</forename><surname>Bilhim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Marisa</forename><surname>Duarte</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lúcia</forename><surname>Fernandes</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">José</forename><surname>Pereira</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">António</forename><forename type="middle">G</forename><surname>Oliveira</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00330-012-2714-9</idno>
		<idno type="PMID">23370938</idno>
		<idno type="ark">ark:/67375/VQC-7QH980ZG-Z</idno>
		<idno type="istexId">DB0C5E062CAE6D9E71CB69C85785BF66322AEB5C</idno>
		<ptr type="open-access" target="http://repositorio.chlc.min-saude.pt/bitstream/10400.17/1192/1/Eur%20Radiol%202013.pdf" />
	</analytic>
	<monogr>
		<title level="j">European Radiology</title>
		<title level="j" type="abbrev">Eur Radiol</title>
		<idno type="ISSN">0938-7994</idno>
		<idno type="ISSNe">1432-1084</idno>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="2561" to="2572" />
			<date type="published" when="2013-01-31" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Prostatic Arterial Embolization to Treat Benign Prostatic Hyperplasia</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">João</forename><forename type="middle">M</forename><surname>Pisco</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Luis</forename><forename type="middle">C</forename><surname>Pinheiro</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tiago</forename><surname>Bilhim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Marisa</forename><surname>Duarte</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jorge</forename><forename type="middle">R</forename><surname>Mendes</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Antonio</forename><forename type="middle">G</forename><surname>Oliveira</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jvir.2010.09.030</idno>
		<idno type="PMID">21195898</idno>
		<ptr type="open-access" target="http://repositorio.chlc.min-saude.pt/bitstream/10400.17/1193/1/JVIR%202011%2011.pdf" />
	</analytic>
	<monogr>
		<title level="j">Journal of Vascular and Interventional Radiology</title>
		<title level="j" type="abbrev">Journal of Vascular and Interventional Radiology</title>
		<idno type="ISSN">1051-0443</idno>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="11" to="19" />
			<date type="published" when="2011-01" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Minimally invasive devices for treating lower urinary tract symptoms in benign prostate hyperplasia: technology update</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Aoun</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Q</forename><surname>Marcelis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Roumeguere</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Res Rep Urol</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="125" to="136" />
			<date type="published" when="2015" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Transarterial Prostatic Embolization: Initial Experience in a Canine Model</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Fei</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Francisco</forename><forename type="middle">M</forename><surname>Sánchez</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Verónica</forename><surname>Crisóstomo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Idoia</forename><surname>Díaz-Güemes</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Carmen</forename><surname>López-Sánchez</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jesús</forename><surname>Usón</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Manuel</forename><surname>Maynar</surname></persName>
		</author>
		<idno type="DOI">10.2214/ajr.10.5947</idno>
		<idno type="PMID">21785100</idno>
		<ptr type="open-access" target="http://pdfs.semanticscholar.org/1bf7/1e09ba40100583b566529e44e548106184bc.pdf" />
	</analytic>
	<monogr>
		<title level="j">American Journal of Roentgenology</title>
		<title level="j" type="abbrev">American Journal of Roentgenology</title>
		<idno type="ISSN">0361-803X</idno>
		<idno type="ISSNe">1546-3141</idno>
		<imprint>
			<biblScope unit="volume">197</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="495" to="501" />
			<date type="published" when="2011-08" />
			<publisher>American Roentgen Ray Society</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Critical Analysis of the Relationship Between Sexual Dysfunctions and Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mauro</forename><surname>Gacci</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ian</forename><surname>Eardley</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Francois</forename><surname>Giuliano</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Dimitris</forename><surname>Hatzichristou</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Steven</forename><forename type="middle">A</forename><surname>Kaplan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mario</forename><surname>Maggi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kevin</forename><forename type="middle">T</forename><surname>Mcvary</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Vincenzo</forename><surname>Mirone</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hartmut</forename><surname>Porst</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Claus</forename><forename type="middle">G</forename><surname>Roehrborn</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.eururo.2011.06.037</idno>
		<idno type="PMID">21726934</idno>
	</analytic>
	<monogr>
		<title level="j">European Urology</title>
		<title level="j" type="abbrev">European Urology</title>
		<idno type="ISSN">0302-2838</idno>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="809" to="825" />
			<date type="published" when="2011-10" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Impact of Changing Trends in Medical Therapy on Surgery for Benign Prostatic Hyperplasia Over Two Decades</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Se</forename><forename type="middle">Young</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tae-Hyoung</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Soon</forename><forename type="middle">Chul</forename><surname>Myung</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Young</forename><forename type="middle">Tae</forename><surname>Moon</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kyung</forename><forename type="middle">Do</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Young</forename><forename type="middle">Sun</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hye-Ryoun</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">In</forename><forename type="middle">Ho</forename><surname>Chang</surname></persName>
		</author>
		<idno type="DOI">10.4111/kju.2012.53.1.23</idno>
		<idno type="PMID">22323970</idno>
		<idno type="PMCID">PMC3272552</idno>
		<ptr type="open-access" target="http://synapse.koreamed.org/Synapse/Data/PDFData/0020KJU/kju-53-23.pdf" />
	</analytic>
	<monogr>
		<title level="j">Korean Journal of Urology</title>
		<title level="j" type="abbrev">Korean J Urol</title>
		<idno type="ISSN">2005-6737</idno>
		<idno type="ISSNe">2005-6745</idno>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">23</biblScope>
			<date type="published" when="2012" />
			<publisher>The Korean Urological Association (KAMJE)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Transurethral Resection of the Prostate (TURP) Versus Original and PErFecTED Prostate Artery Embolization (PAE) Due to Benign Prostatic Hyperplasia (BPH): Preliminary Results of a Single Center, Prospective, Urodynamic-Controlled Analysis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Francisco</forename><forename type="middle">C</forename><surname>Carnevale</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Alexandre</forename><surname>Iscaife</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Eduardo</forename><forename type="middle">M</forename><surname>Yoshinaga</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Airton</forename><forename type="middle">Mota</forename><surname>Moreira</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Alberto</forename><forename type="middle">A</forename><surname>Antunes</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Miguel</forename><surname>Srougi</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00270-015-1202-4</idno>
		<idno type="PMID">26506952</idno>
	</analytic>
	<monogr>
		<title level="j">CardioVascular and Interventional Radiology</title>
		<title level="j" type="abbrev">Cardiovasc Intervent Radiol</title>
		<idno type="ISSN">0174-1551</idno>
		<idno type="ISSNe">1432-086X</idno>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="44" to="52" />
			<date type="published" when="2015-10-27" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Benign Prostatic Hyperplasia: Prostatic Arterial Embolization versus Transurethral Resection of the Prostate—A Prospective, Randomized, and Controlled Clinical Trial</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yuan-An</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yan</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Rui</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yu-Dong</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Qing</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Min</forename><surname>Hou</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yi</forename><surname>Wang</surname></persName>
		</author>
		<idno type="DOI">10.1148/radiol.13122803</idno>
		<idno type="PMID">24475799</idno>
		<ptr type="open-access" target="https://pubs.rsna.org/doi/pdf/10.1148/radiol.13122803" />
	</analytic>
	<monogr>
		<title level="j">Radiology</title>
		<title level="j" type="abbrev">Radiology</title>
		<idno type="ISSN">0033-8419</idno>
		<idno type="ISSNe">1527-1315</idno>
		<imprint>
			<biblScope unit="volume">270</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="920" to="928" />
			<date type="published" when="2014-03" />
			<publisher>Radiological Society of North America (RSNA)</publisher>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
